LYSARC
LYSARC is the operational arm of the French LYSA cooperative group, coordinating lymphoma clinical trials and translational research across 500+ researchers and 120 European centers, funded by public grants, pharma partnerships, and membership fees.
- Company typePrivate
- Founded1984
- HeadquartersPierre-Bénite, Rhône, France
- Headcount101–250
- GTM typeB2B
- OfferingServices
What LYSARC does
LYSARC is a French non-profit association (Association Loi 1901) that serves as the operational arm of the LYSA (Lymphoma Study Association) cooperative group, coordinating clinical and translational research in lymphoma across a network of more than 500 researchers in 120 European clinical centers. The organization was formed in 2012 via the merger of GELA (founded 1984) and GOELAMS, and operates from Pierre-Bénite, France with 101–250 employees, functioning as a member of the Institut Carnot CALYM consortium. Its scope covers the 80+ recognized lymphoma subtypes and addresses the roughly 14,000 new lymphoma cases diagnosed annually in France.
LYSARC's core products are its clinical trial operations and the REALYSA real-world cohort platform, which underpins multiple ongoing sub-studies (BIDIFLY, POLARYSA, FRENCH CONNECT, ELKIN, etc.) and links clinical data with the French national health data system (SNDS) via a partnership with CNAM. The organization operates a translational research program spanning biobanking (PELyon), biomarker identification, and ctDNA analysis, supported by a multi-disciplinary team and a participant-facing digital platform called Klineo.
LYSARC's revenue model is diversified across three pillars: public subsidies (notably INCa funding), industry-sponsored research partnerships with major pharmaceutical companies (Roche, Takeda, BMS, AstraZeneca, AbbVie, Celgene), and community support including membership fees (€25/year for physicians, €10/year for interns) and donations. As a non-profit, LYSARC reinvests surplus into lymphoma research rather than distributing profit, with its scientific outputs disseminated through peer-reviewed publications, congress presentations, and the annual LYSA Days congress.
LYSARC firmographics
Firmographics- Name
- LYSARC
- Legal name
- LYSARC (Association Loi 1901 LYSA-LYSARC)
- Website
- https://experts-recherche-lymphome.org
- Company type
- Private
- Founded year
- 1984
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- LYSARC is the operational arm of the French LYSA cooperative group, coordinating lymphoma clinical trials and translational research across 500+ researchers and 120 European centers, funded by public grants, pharma partnerships, and membership fees.
- Ownership category
- akta.pro rank
LYSARC industry classification
Industry- Product category
- Clinical Research Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Trial Site Operations & Study Coordination (HLAGACAE)
- akta.pro secondary industries
- Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where LYSARC is headquartered
LocationHeadquarters
- HQ city
- Pierre-Bénite, Rhône
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
LYSARC business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Public Subsidies: LYSA-LYSARC receives public funding from institutions that subsidize its activities as a non-profit association engaged in public interest research
- Research Grants and Partnerships: Collaboration with pharmaceutical partners (Roche, Takeda, BMS, AstraZeneca, AbbVie, Celgene) for specific clinical studies, with partners receiving aggregated anonymized results only
- Membership Fees: Annual membership fees from LYSA members: 25.00€ for physicians, 10€ for interns, free for ARC and IDE professionals
- Donations: Donations from individuals and organizations supporting lymphoma research, processed through HelloAsso platform
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Physician Membership |
| Subscription | Annual | Intern Membership |
| Subscription | Annual | ARC and IDE Membership |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
LYSARC product offering
Product offeringCore offering
LYSARC is the operational research structure of the LYSA cooperative group, conducting Phase I–III lymphoma clinical trials from first-in-human administration through registration studies. It operates the REALYSA national real-life lymphoma cohort platform that enables simultaneous sub-studies across lymphoma subtypes, manages translational research (biomarkers, ctDNA, genetics), and links data with the French National Health Data System (SNDS). It also offers the Klineo platform for clinical trial access, serving hospitals, pharmaceutical partners, and academic researchers across 120+ European centers.
Product overview
LYSARC is an operational research structure for lymphoma research that conducts LYSA cooperative group's projects. It operates primarily through the REALYSA national cohort study platform, which enables multiple sub-studies covering different lymphoma types (follicular, diffuse large B-cell, mantle cell, marginal zone, Hodgkin, T-cell lymphomas) and research themes (ctDNA analysis, quality of life, pesticide exposure, treatment outcomes). The organization also offers the Klineo research platform for clinical trial access. These research studies and platforms are interconnected through shared patient data and coordinated analysis across clinical, imaging, biological, and genetic modalities.
Differentiator
Problem solved
Functional benefit
Products and services
- LYSARC Operational Research Services Comprehensive operational research services for the LYSA cooperative group, managing lymphoma clinical trials from first-in-human administration through treatment registration studies, translational research, and regulatory-compliant study execution across European centers.
- REALYSA National Cohort Platform National real-world lymphoma cohort platform enabling simultaneous sub-studies across lymphoma subtypes, aggregating clinical, imaging, biological, anatomopathology, and genetic data from lymphoma patients across French centers.
- Klineo Research Platform Online research platform offered by LYSARC providing clinical trial access and collaboration tools for healthcare professionals, researchers, and pharmaceutical partners.
Quantifiable outcome
- Rituximab maintenance in mantle cell lymphoma: 89% survival at 4 years vs 80% in observation group
- +2 more outcomes
Companies that use LYSARC
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles4 records
LYSARC technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
LYSARC partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- PELyoncorePELyon is a study bureau partner of LYSARC specializing in real-world studies based on SNDS (French National Health Data System) data. They handle data analysis for the REALYSA comorbidity study and other projects using administrative health data.
- RochecoreRoche partners with LYSARC on the REALYSA study, specifically for the POLARYSA sub-study on diffuse large B-cell lymphomas. Roche receives aggregated anonymized results for regulatory submissions to French health authorities.
- TakedacoreTakeda partners with LYSARC for Brentuximab Vedotin usage reports and studies on Hodgkin lymphoma and T-cell lymphomas. Provides data to ANSM (French drug agency) as part of temporary utilization recommendations (RTU).
- Bristol Myers Squibb (BMS)coreBMS partners with LYSARC for the REALYSA study on second-line treatment of diffuse large B-cell lymphoma. Receives aggregated anonymized results for regulatory submissions.
- AstraZenecacoreAstraZeneca partners with LYSARC for the MCL_TOUR study on mantle cell lymphoma treatment in collaboration with Dr. Morgane Cheminant. Receives aggregated anonymized results for regulatory submissions.
- AbbViecoreAbbVie partners with LYSARC for studies on third-line treatment of diffuse large B-cell lymphoma (DLBCL-3L study). Receives aggregated anonymized results for regulatory submissions.
- CelgenecoreCelgene collaborated with LYSA on the RELEVANCE study comparing lenalidomide plus rituximab (R²) versus immunochemotherapy for follicular lymphoma, published in New England Journal of Medicine.
- CNAM (Caisse Nationale de l'Assurance Maladie)coreCNAM provides access to SNDS (French National Health Data System) data for real-world evidence studies conducted by LYSARC, enabling analysis of healthcare consumption and costs at national level.
- Stanford UniversityminorStanford University (Leland Stanford Junior University) collaborates with LYSARC on the ELKIN study to identify biological reasons for treatment failure in elderly Hodgkin lymphoma patients.
- Institut Carnot CALYMcoreLYSA and LYSARC are member entities of Institut Carnot CALYM, a Carnot Institute consortium dedicated to lymphoma research, bringing together complementary expertise from fundamental to clinical research.
- EPICENE (INSERM)minorEPICENE research team (Bordeaux) coordinates the PELYCANO study on pesticide exposure and lymphoma, collaborating with multiple French research institutions.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
LYSARC competitors and assessment
Company assessmentDirect peers
- EORTC (European Organisation for Research and Treatment of Cancer): European non-profit cancer clinical research organization that runs multi-center oncology trials across Europe. Directly comparable to LYSARC in mission (academic CRO running independent, sponsor-supported oncology trials) and operational model, with broader cancer scope rather than lymphoma-only focus.
- Nordic Lymphoma Group (NLG): Academic lymphoma cooperative group operating across Nordic countries. Closely comparable to LYSA-LYSARC as a lymphoma-specific cooperative network running clinical trials across multiple national centers, though geographically focused on the Nordics rather than France.
- International Extranodal Lymphoma Study Group (IELSG): International academic group coordinating clinical trials on extranodal lymphomas. Direct lymphoma-only peer to LYSARC with similar cooperative-group structure and multi-country trial operations.
- HOVON (Dutch-Belgian Hemato-Oncology Cooperative Group): Academic cooperative group running hematology and lymphoma clinical trials across the Netherlands and Belgium. Comparable to LYSARC as a regional European academic CRO with similar operating model and sponsor partnerships.
- German Lymphoma Study Group (GLSG / DSHNHL): German lymphoma cooperative group conducting clinical trials and translational research across German centers. Direct peer to LYSA-LYSARC in lymphoma specialization, academic cooperative model, and multi-center clinical trial execution.
Broad incumbents
- SWOG Cancer Research Network: Large US-based National Cancer Institute cooperative group running oncology trials across hundreds of US sites. Comparable to LYSARC as an academic cooperative group running sponsor-supported oncology trials, but far larger and broader in cancer scope.
Others
- Institut National du Cancer (INCa): French national cancer agency that funds and coordinates cancer research in France, including financial support to LYSARC's REALY-QoL project. Not a peer operator but a key funder and policy counterpart whose priorities directly shape LYSARC's research agenda.
- Institut Carnot CALYM: French Carnot Institute consortium dedicated to lymphoma research of which LYSA and LYSARC are member entities. Operates as a parent consortium providing shared infrastructure and labeling rather than as a competing entity.
Emerging players
- Lymphoma Research Foundation (LRF): US non-profit focused on lymphoma research funding, education, and patient support. Compares to LYSARC as a lymphoma-specific non-profit, but its role is fundraising and grantmaking rather than running clinical trials, making it a thematic rather than operational peer.
Regional players
- Australasian Leukaemia & Lymphoma Group (ALLG): Australia/New Zealand cooperative group running hematology clinical trials. Operates the same academic cooperative model as LYSARC for hematological malignancies, but serves the Australasian geography.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
LYSARC social profiles
Digital presenceLYSARC compliance and trust
Trust signalCompliance1 record
LYSARC financial estimates
Financial estimateRevenue estimate
Valuation estimate
LYSARC leadership team
Management profileNumber of profiles
Profiles3 records
LYSARC funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LYSARC M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LYSARC
What does LYSARC do?
LYSARC is the operational research structure of the LYSA cooperative group, conducting Phase I–III lymphoma clinical trials from first-in-human administration through registration studies. It operates the REALYSA national real-life lymphoma cohort platform that enables simultaneous sub-studies across lymphoma subtypes, manages translational research (biomarkers, ctDNA, genetics), and links data with the French National Health Data System (SNDS). It also offers the Klineo platform for clinical trial access, serving hospitals, pharmaceutical partners, and academic researchers across 120+ European centers.
Is LYSARC a public or private company?
LYSARC is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was LYSARC founded?
LYSARC was founded in 1984. It employs 101 to 250 people.
Where is LYSARC based?
LYSARC is headquartered in Pierre-Bénite, Rhône, France, in the Europe region.
How does LYSARC make money?
Four revenue lines are on record. Public Subsidies are the primary driver. The others are research Grants and Partnerships, membership Fees and donations.
Who are LYSARC's main competitors?
Direct peers on record are EORTC (European Organisation for Research and Treatment of Cancer), Nordic Lymphoma Group (NLG), International Extranodal Lymphoma Study Group (IELSG), HOVON (Dutch-Belgian Hemato-Oncology Cooperative Group) and German Lymphoma Study Group (GLSG / DSHNHL). SWOG Cancer Research Network is listed as a broad incumbent. Others are Institut National du Cancer (INCa) and Institut Carnot CALYM. Lymphoma Research Foundation (LRF) is listed as an emerging player. Australasian Leukaemia & Lymphoma Group (ALLG) is listed as a regional player.
Does LYSARC have an API?
No public API is recorded for LYSARC.
What industry is LYSARC in?
LYSARC's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination, with a secondary code of HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs. Its NAICS code is 54171 and its SIC code is 8731.